Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE)

By sjmartinez • February 7, 2023

Chang L, Cash BD, Lembo A, Kunkel DC, English BA, Lindstrom B, Gu G, Skare S, Gilder K, Turner S, Cataldi F, Lipkis D, Jan T. Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE). Neurogastroenterol Motil. 2023 Feb 5:e14539. doi: 10.1111/nmo.14539. Epub ahead of print. PMID: 36740814.

Tags: abdominal pain, cannabinoid receptor agonists, cannabinoids, Digestive Diseases, Irritable Bowel Syndrome, olorinab, Publications

Tools for endoscopic management of benign luminal GI strictures

ASGE Technology Committee; Akshintala VS, Shahnavaz N, Abdi M, Chen D, Chen YI, Das KK, Desilets D, Girotra M, Vinsard DG, Leung G, Mishra G,[...]

Advanced nutrition support therapy practices of registered dietitian nutritionists: A survey of the Academy of Nutrition and Dietetics’ Dietitians in Nutrition Support Dietetics Practice Group and the American Society for Parenteral and Enteral Nutrition Dietetics Practice Section

Lessar S, Brody RA, Dobak S, Foley S, Malone A, Peterson SJ, Yaceczko S, Price K. Advanced nutrition support therapy practices of registered dietitian nutritionists:[...]

Annual cases of colon cancer by age group after Medicaid expansion in the USA in 2014: a difference-in-differences study

Asiimwe E, May F, Bendavid E. Annual cases of colon cancer by age group after Medicaid expansion in the USA in 2014: a difference-in-differences study.[...]